CIK 0001744659
AKRO Akero Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Dec 30, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at Akero Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 5Weak | sell 610b5-1 | Rolph Timothy Chief Scientific Officer | $118k | 3,800 | -2% | - | |
| 8Weak | sell 610b5-1 | Yale Catriona Chief Development Officer | $264k | 9,074 | -9% | - | |
| 15Weak | sell 610b5-1 | Lamy Patrick Senior VP, Commercial Strategy | $29k | 1,000 | -3% | - | |
| 53Moderate | sell 6 | Cheng Andrew President and CEO | $242k | 7,855 | -1% | - | |
| 46Moderate | sell 6 | White William Richard Chief Financial Officer | $87k | 2,817 | -7% | - | |
| 39Weak | sell 6 | Yale Catriona Chief Development Officer | $87k | 2,810 | -4% | - | |
| 35Weak | sell 6 | Lamy Patrick Senior VP, Commercial Strategy | $28k | 925 | -5% | - | |
| 43Moderate | sell 6 | Young Jonathan Chief Operating Officer | $77k | 2,503 | -1% | - | |
| 6Weak | sell 610b5-1 | Rolph Timothy Chief Scientific Officer | $149k | 4,818 | -3% | - | |
| 29Weak | sell 610b5-1 | Young Jonathan Chief Operating Officer | $321k | 10,000 | -5% | - | |
| 27Weak | sell 610b5-1 | Cheng Andrew President and CEO | $802k | 25,000 | -4% | - | |
| 13Weak | sell 310b5-1 | Yale Catriona Chief Development Officer | $251k | 9,061 | -11% | - | |
| 15Weak | sell 310b5-1 | Yale Catriona Chief Development Officer | $352k | 10,000 | -12% | - | |
| 35Weak | sell 310b5-1 | Cheng Andrew President and CEO | $3.4M | 108,366 | -16% | - | |
| 30Weak | sell 310b5-1 | Young Jonathan Chief Operating Officer | $1.6M | 50,716 | -19% | - | |
| 25Weak | sell 310b5-1 | Yale Catriona Chief Development Officer | $652k | 20,000 | -25% | - | |
| 35Weak | sell 310b5-1 | Cheng Andrew President and CEO | $2.9M | 91,634 | -15% | - | |
| 25Weak | sell 310b5-1 | Yale Catriona Chief Development Officer | $636k | 20,961 | -26% | - | |
| 30Weak | sell 310b5-1 | Young Jonathan Chief Operating Officer | $1.2M | 40,000 | -15% | - |
Transactions
The last 81 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 26, 2024 | Rolph Timothy Chief Scientific Officer | GGift Common Stock | -14,100 | $0.00 | $0 | 184,237 | Dec 30, 2024 |
| Dec 16, 2024 | Young Jonathan Chief Operating Officer | AGrant or award Common Stock | +24,300 | $0.00 | $0 | 228,083 | Dec 18, 2024 |
| Dec 16, 2024 | Lamy Patrick Senior VP, Commercial Strategy | AGrant or award Common Stock10b5-1 | +17,400 | $0.00 | $0 | 35,258 | Dec 18, 2024 |
| Dec 16, 2024 | Yale Catriona Chief Development Officer | AGrant or award Common Stock10b5-1 | +24,300 | $0.00 | $0 | 95,648 | Dec 18, 2024 |
| Dec 16, 2024 | White William Richard Chief Financial Officer | AGrant or award Common Stock | +24,300 | $0.00 | $0 | 62,635 | Dec 18, 2024 |
| Dec 16, 2024 | Gangloff Scott A. Chief Technology Officer | AGrant or award Common Stock | +24,300 | $0.00 | $0 | 24,300 | Dec 18, 2024 |
| Dec 16, 2024 | Cheng Andrew President and CEO | AGrant or award Common Stock | +98,500 | $0.00 | $0 | 696,062 | Dec 18, 2024 |
| Dec 17, 2024 | Rolph Timothy Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +3,800 | $19.87 | $76k | 182,137 | Dec 18, 2024 |
| Dec 16, 2024 | Cheng Andrew President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +295,600 | $0.00 | $0 | 295,600 | Dec 18, 2024 |
| Dec 16, 2024 | Gangloff Scott A. Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +73,700 | $0.00 | $0 | 73,700 | Dec 18, 2024 |
| Dec 16, 2024 | White William Richard Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +73,700 | $0.00 | $0 | 73,700 | Dec 18, 2024 |
| Dec 16, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +9,074 | $21.10 | $191k | 104,722 | Dec 18, 2024 |
| Dec 17, 2024 | Rolph Timothy Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,800 | $31.10 | $118k | 178,337 | Dec 18, 2024 |
| Dec 16, 2024 | Lamy Patrick Senior VP, Commercial Strategy | SOpen-market sale Common Stock10b5-1 | -1,000 | $29.13 | $29k | 34,258 | Dec 18, 2024 |
| Dec 16, 2024 | Rolph Timothy Chief Scientific Officer | AGrant or award Common Stock10b5-1 | +20,000 | $0.00 | $0 | 198,337 | Dec 18, 2024 |
| Dec 16, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -9,074 | $29.11 | $264k | 95,648 | Dec 18, 2024 |
| Dec 16, 2024 | Lamy Patrick Senior VP, Commercial Strategy | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +52,100 | $0.00 | $0 | 52,100 | Dec 18, 2024 |
| Dec 17, 2024 | Rolph Timothy Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,800 | $0.00 | $0 | 134,955 | Dec 18, 2024 |
| Dec 16, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,074 | $0.00 | $0 | 20,000 | Dec 18, 2024 |
| Dec 16, 2024 | Rolph Timothy Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Dec 18, 2024 |
| Dec 16, 2024 | Young Jonathan Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +73,700 | $0.00 | $0 | 73,700 | Dec 18, 2024 |
| Dec 16, 2024 | Yale Catriona Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +73,700 | $0.00 | $0 | 73,700 | Dec 18, 2024 |
| Dec 10, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock | -7,855 | $30.79 | $242k | 597,562 | Dec 12, 2024 |
| Dec 10, 2024 | Rolph Timothy Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,368 | $30.79 | $73k | 178,337 | Dec 12, 2024 |
| Dec 10, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock | -2,503 | $30.79 | $77k | 203,783 | Dec 12, 2024 |
| Dec 10, 2024 | Lamy Patrick Senior VP, Commercial Strategy | SOpen-market sale Common Stock | -925 | $30.79 | $28k | 17,858 | Dec 12, 2024 |
| Dec 10, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock | -2,810 | $30.79 | $87k | 71,348 | Dec 12, 2024 |
| Dec 10, 2024 | White William Richard Chief Financial Officer | SOpen-market sale Common Stock | -2,817 | $30.79 | $87k | 38,335 | Dec 12, 2024 |
| Dec 10, 2024 | Rolph Timothy Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +2,450 | $19.87 | $49k | 180,787 | Dec 12, 2024 |
| Dec 10, 2024 | Rolph Timothy Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,450 | $31.03 | $76k | 178,337 | Dec 12, 2024 |
| Dec 10, 2024 | Rolph Timothy Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,450 | $0.00 | $0 | 138,755 | Dec 12, 2024 |
| Dec 2, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $32.13 | $321k | 206,286 | Dec 4, 2024 |
| Dec 2, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +25,000 | $21.10 | $528k | 630,417 | Dec 4, 2024 |
| Dec 2, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -25,000 | $32.09 | $802k | 605,417 | Dec 4, 2024 |
| Dec 2, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 111,029 | Dec 4, 2024 |
| Nov 15, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +9,061 | $21.10 | $191k | 83,219 | Nov 19, 2024 |
| Nov 15, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -8,761 | $27.69 | $243k | 74,458 | Nov 19, 2024 |
| Nov 15, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -300 | $28.82 | $8,647 | 74,158 | Nov 19, 2024 |
| Nov 15, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,061 | $0.00 | $0 | 53,421 | Nov 19, 2024 |
| Nov 6, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +10,000 | $0.62 | $6,150 | 84,158 | Nov 8, 2024 |
| Nov 6, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $35.19 | $352k | 74,158 | Nov 8, 2024 |
| Nov 6, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,890 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,110 | $0.00 | $0 | 16,849 | Nov 8, 2024 |
| Nov 1, 2024 | Young Jonathan Chief Operating Officer | MOption exercise Common Stock10b5-1 | +40,716 | $21.09 | $859k | 267,002 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +81,280 | $21.10 | $1.7M | 686,697 | Nov 5, 2024 |
| Nov 1, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -34,943 | $31.25 | $1.1M | 232,059 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -81,280 | $31.47 | $2.6M | 605,417 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +27,086 | $21.10 | $572k | 632,503 | Nov 5, 2024 |
| Nov 1, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -15,481 | $32.27 | $500k | 216,578 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -27,086 | $32.50 | $880k | 605,417 | Nov 5, 2024 |
| Nov 1, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -292 | $32.94 | $9,618 | 216,286 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -81,280 | $0.00 | $0 | 163,115 | Nov 5, 2024 |
| Nov 1, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,086 | $0.00 | $0 | 136,029 | Nov 5, 2024 |
| Nov 1, 2024 | Young Jonathan Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,716 | $0.00 | $0 | 0 | Nov 5, 2024 |
| Oct 30, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +4,515 | $21.10 | $95k | 78,673 | Nov 1, 2024 |
| Oct 30, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -4,515 | $32.53 | $147k | 74,158 | Nov 1, 2024 |
| Nov 1, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +15,485 | $21.10 | $327k | 89,643 | Nov 1, 2024 |
| Nov 1, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -15,485 | $32.62 | $505k | 74,158 | Nov 1, 2024 |
| Oct 30, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,515 | $0.00 | $0 | 57,266 | Nov 1, 2024 |
| Nov 1, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,485 | $0.00 | $0 | 41,781 | Nov 1, 2024 |
| Oct 16, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +24,992 | $21.10 | $527k | 630,409 | Oct 18, 2024 |
| Oct 16, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -24,992 | $31.14 | $778k | 605,417 | Oct 18, 2024 |
| Oct 17, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +3,103 | $21.10 | $65k | 608,520 | Oct 18, 2024 |
| Oct 17, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -3,103 | $31.12 | $97k | 605,417 | Oct 18, 2024 |
| Oct 18, 2024 | Cheng Andrew President and CEO | MOption exercise Common Stock10b5-1 | +63,539 | $21.10 | $1.3M | 668,956 | Oct 18, 2024 |
| Oct 18, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -63,313 | $31.53 | $2.0M | 605,643 | Oct 18, 2024 |
| Oct 18, 2024 | Cheng Andrew President and CEO | SOpen-market sale Common Stock10b5-1 | -226 | $32.12 | $7,259 | 605,417 | Oct 18, 2024 |
| Oct 16, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -24,992 | $0.00 | $0 | 160,351 | Oct 18, 2024 |
| Oct 17, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -3,103 | $0.00 | $0 | 157,248 | Oct 18, 2024 |
| Oct 18, 2024 | Cheng Andrew President and CEO | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -63,539 | $0.00 | $0 | 93,709 | Oct 18, 2024 |
| Oct 15, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +14,825 | $0.62 | $9,117 | 90,119 | Oct 16, 2024 |
| Oct 14, 2024 | Young Jonathan Chief Operating Officer | MOption exercise Common Stock10b5-1 | +40,000 | $21.09 | $844k | 266,286 | Oct 16, 2024 |
| Oct 15, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -14,525 | $30.50 | $443k | 75,594 | Oct 16, 2024 |
| Oct 14, 2024 | Young Jonathan Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -40,000 | $30.15 | $1.2M | 226,286 | Oct 16, 2024 |
| Oct 15, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -300 | $30.93 | $9,278 | 75,294 | Oct 16, 2024 |
| Oct 14, 2024 | Yale Catriona Chief Development Officer | MOption exercise Common Stock10b5-1 | +5,000 | $0.62 | $3,075 | 80,294 | Oct 16, 2024 |
| Oct 14, 2024 | Yale Catriona Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -6,136 | $30.03 | $184k | 74,158 | Oct 16, 2024 |
| Oct 15, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,825 | $0.00 | $0 | 13,890 | Oct 16, 2024 |
| Oct 14, 2024 | Young Jonathan Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 40,716 | Oct 16, 2024 |
| Oct 14, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 8,890 | Oct 16, 2024 |
| Oct 15, 2024 | Yale Catriona Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 17,959 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Cheng AndrewPresident and CEO
- Gangloff Scott A.Chief Technology Officer
- Lamy PatrickSenior VP, Commercial Strategy
- Rolph TimothyChief Scientific Officer
- White William RichardChief Financial Officer
- Yale CatrionaChief Development Officer
- Young JonathanChief Operating Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.